This site is intended for a healthcare professional audience in the United States.

GIAPREZA (angiotensin II) is the first and only FDA-approved synthetic human angiotensin II treatment that activates the RAAS to increase MAP

The Renin-Angiotensin-Aldosterone System (RAAS) Has a Critical Role in Regulating Hemodynamic Stability1,2

There are three endogenous systems that regulate hemodynamics

With the introduction of GIAPREZA, all three systems can now be leveraged pharmacologically3,4

GIAPREZA leverages the RAAS, which is not targeted by other therapies, to increase MAP3,4

Important Safety Information See more

Warnings and Precautions The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in the randomized, double-blind, placebo-controlled ATHOS-3 study. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo treated patients in the ATHOS-3 study [13% (21/163 patients) vs. 5% (8/158 patients)]. The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism prophylaxis.

IndicationGIAPREZA™ (angiotensin II) increases blood pressure in adults with septic or other distributive shock.

Important Safety Information

Indication GIAPREZA™ (angiotensin II) increases blood pressure in adults with septic or other distributive shock.

Contraindications None.

Warnings and Precautions The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in the randomized, double-blind, placebo-controlled ATHOS-3 study. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo treated patients in the ATHOS-3 study [13% (21/163 patients) vs. 5% (8/158 patients)]. The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism prophylaxis.

Adverse Reactions The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in ≥4% of patients treated with GIAPREZA and ≥1.5% more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.

Drug Interactions Angiotensin converting enzyme inhibitors may increase response to GIAPREZA.

Angiotensin II receptor blockers may reduce response to GIAPREZA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional Important Safety Information, please see the full Prescribing Information.

References: 1. Adapted from Hendry C et al. Nurs Stand. 2012;27(11):35-40. 2. Dominguez M. Renin-Angiotensin-Aldosterone System. medbullets.com. https://step1.medbullets.com/renal/115016/renin-angiotensin-aldosterone-system. August 30, 2017. Accessed April 5, 2019. 3. GIAPREZA™ (angiotensin II) [prescribing information]. San Diego, CA: La Jolla Pharmaceutical Company; 2017. 4. Khanna A et al. N Engl J Med. 2017;377:419-430. 5. Wan L et al. Crit Care. 2009;13:R190.

Are you a healthcare professional in the United States?